Tarlatamab for Patients with Previously Treated Small-Cell Lung …
Oct 20, 2023 · Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously …
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN …
Apr 11, 2025 · About IMDELLTRA®(tarlatamab-dlle) IMDELLTRA is a first-in-class immunotherapy engineered by Amgen researchers that binds to both DLL3 on tumor cells and …
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces ...
Oct 1, 2020 · This study highlights the ability of the DLL3/CD3 ITE to induce strictly DLL3-dependent T-cell redirected lysis of tumor cells and recruitment of T-cells into noninflamed …
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell
Jun 1, 2023 · Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb …
Tarlatamab Improves Overall Survival in Extensive-Stage SCLC
4 days ago · Tarlatamab is a bispecific T-cell engager that binds to delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, activating T cells to attack DLL3-expressing cancer cells.
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T …
Jun 4, 2024 · Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and …
NCI-H82 Short term 2:1 100 DLL3 TriTCE Co-Stim is a trispecific T cell engager (TriTCE) designed to optimally engage CD3 and CD28 to redirect and enhance cytotoxic T cell …
FDA approves first DLL3 × CD3 bispecific T-cell engager for
May 24, 2024 · This first-in-class DLL3 × CD3-targeted therapy expands the scope of bispecific T-cell engagers, antibodies that recruit T cells to kill off cancer cells.
BiTE® molecules are comprised of a single chain variable fragment (scFv) that binds CD3, a short linker, and a scFv that binds a tumor-associated antigen (TAA).2 BiTE® molecules can include …
First-in-class T cell engager approved for lung cancer - Nature
Jun 17, 2024 · Amgen’s T cell engager Imdelltra (tarlatamab) has gained FDA accelerated approval for an aggressive type of cell lung cancer that is notoriously difficult to treat. The …